Enavogliflozin

CAS No. 1415472-28-4

Enavogliflozin( DWP-16001 )

Catalog No. M28202 CAS No. 1415472-28-4

Enavogliflozin is an orally available small molecule and sodium glucose transporter 2 inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 415 Get Quote
5MG 377 Get Quote
10MG 591 Get Quote
25MG 1026 Get Quote
50MG 1376 Get Quote
100MG 1823 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Enavogliflozin
  • Note
    Research use only, not for human use.
  • Brief Description
    Enavogliflozin is an orally available small molecule and sodium glucose transporter 2 inhibitor.
  • Description
    Enavogliflozin is an orally available small molecule and sodium glucose transporter 2 inhibitor.
  • In Vitro
    Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
  • In Vivo
    ——
  • Synonyms
    DWP-16001
  • Pathway
    GPCR/G Protein
  • Target
    SGLT
  • Recptor
    AChR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1415472-28-4
  • Formula Weight
    446.92
  • Molecular Formula
    C24H27ClO6
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (223.75 mM)
  • SMILES
    OC[C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@H]1c(c1c2OCC1)cc(Cc1ccc(C3CC3)cc1)c2Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Abu-Niaaj L, et al. Isolation and biological effects of 7-O-methyleriodictyol, a flavanone isolated from Artemisia monosperma, on rat isolated smooth muscles. Planta Med. 1993 Feb;59(1):42-5.
molnova catalog
related products
  • Empagliflozin

    Empagliflozin (BI-10773) is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM.

  • Licogliflozin

    A novel sodium glucose transporter type 1 and type 2 (SGLT1/2) inhibitor for the oral treatment of type 2 diabetes.

  • Luseogliflozin

    A potent, selective, orally acitve SGLT2 inhibitor with IC50 of 2.26 nM, 1650-fold selectivity over SGLT1.